Page 106 - SPONDYLOARTHRITIS IN COLOMBIA -

Table 1 Demographic and clinical features of SpA patients (n=50)
Characteristics
Male N (%)
Age (years)
University education N (%) Symptom duration (years) Patient global (0-10 NRS) Pain (0-10 NRS)
Spinal pain (0-10 NRS) BASDAI
BASFI
ASDAS
ASAS-HI
AS (n=30) 17 (57) 46.0 (14.8) 12 (40) 18.9 (9.5) 4.8 (2.7) 4.8 (3.2) 4.6 (3.3) 4.7 (2.4) 5.1 (2.6) 2.3 (1.1) 8.4 (5.5)
Non-radiographic axial SpA (n=14)
6 (43)
45.1 (9.0)
4 (29)
12.7 (8.6)
5.0 (2.3)
2.6 (2.0)
3.0 (1.7)
4.5 (1.7)
4.3 (1.7)
2.2 (0.7)
8.4 (3.2)
Peripheral SpA (n=6)
4 (67) 38.5 (11.3)
0 (0)
7.8 (6.5) 4.0 (2.6) 0.5 (0.7) 0.5 (0.7) 4.0 (2.9) 3.6 (3.0) 2.0 (1.2) 6.6 (7.4)
All SpA (n=50) 27 (54) 44.8 (13.1) 16 (32) 15.8 (9.7) 4.8 (2.5) 4.0 (3.1) 3.9 (3.1) 4.6 (2.2) 4.7 (2.5) 2.2 (1.0) 8.2 (5.1)
All values given as mean±SD unless specified
SpA, spondyloarthritis; AS, ankylosing spondylitis; NRS, numerical rating scale; BASDAI, Bath ankylosing spondylitis activity disease indez; BASFI, Bath ankylosing spondylitis functional index; ASDAS, Ankylosing Spondylitis Disease Activity Score, ASAS HI, The Assessment of Spondyloarthritis international Society Health Index
Test-retest Reliability
The mean (SD) baseline ASAS-HI was 8.9 (5.0) and the second ASAS-HI was 7.4 (5.4) in the 18 patients in the reliability arm. The ICC was good 0.84 (95% CI 0.71 to 0.93, p<0.001).
Sensitivity to change
Ten patients required change of treatment: 7 patients started a TNF blocker, 2 patients started NSAIDS and 1 patient a DMARD. The SRM was 2.58 (1.75 to 3.37) for all patients requiring modification of treatment (n=10). For those patients in which the intervention was starting a TNF blocker (n=7) the SRM was higher: 2.94 (2.13 to 4.24) than those starting a NSAID or DMARD (n=3), in which the SRM was 2.22 (1.23 to 3.21).
104